Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

BioDrugs

Volumn 31, Issue 6, 2017, Pages 521-531

  Drake, Penelope M ^a   Rabuka, David ^a  

^a Catalent Biologics West   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; BENZODIAZEPINE DERIVATIVE; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; FIRTECAN; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; INOTUZUMAB OZOGAMICIN; MALEIMIDE; MAYTANSINE; MIRVETUXIMAB SORAVTANSINE; PYRROLOBENZODIAZEPINE; ROVALPITUZUMAB TESIRINE; SACITUZUMAB GOVITECAN; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VADASTUXIMAB TALIRINE; VEDOTIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANAPLASTIC LARGE CELL LYMPHOMA; AREA UNDER THE CURVE; BLOOD TOXICITY; CHRONIC DISEASE; COMBINATION DRUG THERAPY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; FEEDBACK SYSTEM; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; METASTATIC BREAST CANCER; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SOLID MALIGNANT NEOPLASM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; IMMUNOTHERAPY; PROCEDURES; TOXIC HEPATITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; IMMUNOCONJUGATES; IMMUNOTHERAPY;

EID: 85033407367     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-017-0254-1     Document Type: Review

References (64)

1. Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80.
2. Drake PM, Rabuka D. An emerging playbook for antibody. Curr Opin Chem Biol. 2015;28:174–80.
3. Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs. 2016;30:275–93.
4. Govindan SV, Sharkey RM, Goldenberg DM. Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther. 2016;16:883–93.
5. Shor B, Gerber H-P, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67:107–16.
6. Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77:1603–10.
7. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16:315–37.
8. Seattle Genetics stops all trials of ‘33A blood cancer drug after patient deaths. In: FierceBiotech. 2017. http://www.fiercebiotech.com/biotech/seattle-genetics-stops-all-trials-33a-blood-cancer-drug-after-patient-deaths. Accessed 25 Oct 2017.
9. Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting. In: investor.seattlegenetics.com. 2016. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2227547. Accessed 25 Oct 2017.
10. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev. 2015;68:3–19.
11. Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015;71:444–52.
12. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14–23.
13. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–84.
14. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002;13:855–69.
15. Zhao H, Gulesserian S, Malinao MC, Kumar-Ganesan S, Song J, Chang MS, et al. A potential mechanism for ADC-induced neutropenia: role of neutrophils in their own demise. Mol Cancer Ther. 2017. https://doi.org/10.1158/1535-7163.MCT-17-0133.
16. Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123–33.
17. Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273:298–313.
18. Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, et al. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody–maytansinoid conjugates. Bioconjug Chem. 2017;28:1371–81.
19. Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–5.
20. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759–65.
21. Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184–9.
22. Rago B, Tumey LN, Wei C, Barletta F, Clark T, Hansel S, et al. Quantitative conjugated payload measurement using enzymatic release of antibody-drug conjugate with cleavable linker. Bioconjug Chem. 2017;28:620–6.
23. Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol. 2014;32:1059–62.
24. Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem. 2014;25:1871–80.
25. Stein AS, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, et al. A phase 1 trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML). Blood. 2015;126:324.
26. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer:a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2016;18:42–51.
27. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.
28. Ma Y, Khojasteh SC, Hop CECA, Erickson HK, Polson A, Pillow TH, et al. Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice. Drug Metab Dispos. 2016;44:1958–62.
29. Hinrichs MJM, Ryan PM, Zheng B, Afif-Rider S, Yu XQ, Gunsior M, et al. fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates. Clin Cancer Res. 2017. https://doi.org/10.1158/1078-0432.CCR-17-0219.
30. Cilliers C, Guo H, Liao J, Christodolu N, Thurber GM. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 2016. https://doi.org/10.1208/s12248-016-9940-z.
31. Gerber H-P, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6.
32. Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2:741–55.
33. Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, et al. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother. 2014;63:925–38.
34. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7:315ra188.
35. Li F, Ulrich M, Jonas M, Stone IJ, Linares G, Zhang X, et al. Tumor-Associated macrophages can contribute to antitumor activity through FcγR-mediated processing of antibody-drug conjugates. Mol Cancer Ther. 2017;16:1347–54.
36. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29:1578–86.
37. Bartlett NL, Smith MR, Siddiqi T, Advani RH, O’Connor OA, Sharman JP, et al. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017;58:1607–16.
38. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394–402.
39. Chang C-H, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Combining ABCG2 inhibitors with IMMU-132, an Anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers. Mol Cancer Ther. 2016;15:1910–9.
40. Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic lethality exploitation by an Anti–Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2–wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405–15.
41. Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aag2611.
42. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. 2017;31:501–8.
43. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358–64.
44. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs. 2014;5:13–21.
45. DeVay RM, Delaria K, Zhu G, Holz C, Foletti D, Sutton J, et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug Chem. 2017;28:1102–14.
46. de Goeij BECG, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther. 2015;14:1130–40.
47. Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates. Nat Chem. 2016;8:1112–9.
48. Kolakowski RV, Haelsig KT, Emmerton KK, Leiske CI, Miyamoto JB, Cochran JH, et al. The methylene alkoxy carbamate self-immolative unit: utilization for the targeted delivery of alcohol-containing payloads with antibody-drug conjugates. Angew Chem Int Ed. 2016;55:7948–51.
49. Zhang D, Pillow TH, Ma Y, Cruz-Chuh JD, Kozak KR, Sadowsky JD, et al. Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody-drug conjugates. ACS Med Chem Lett. 2016;7:988–93.
50. Zhang D, Yu S-F, Ma Y, Xu K, Dragovich PS, Pillow TH, et al. Chemical structure and concentration of intratumor catabolites determine efficacy of antibody drug conjugates. Drug Metab Dispos. 2016;44:1517–23.
51. Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, et al. A new triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Mol Cancer Ther. 2016;15:1311–20.
52. Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20:161–7.
53. Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem. 2014;25:1331–41.
54. Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33:694–6.
55. Puthenveetil S, He H, Loganzo F, Musto S, Teske J, Green M, et al. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS One. 2017;12:e0178452.
56. Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, et al. Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol Cancer Ther. 2016;15:958–70.
57. Moore KN, Martin LP, Matulonis UA, Konner JA. IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): single-agent activity in platinum-resistant. J Clin Oncol. 2016;35:15.
58. Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015;33:1609–19.
59. Burki TK. Sacituzumab govitecan activity in advanced breast cancer. Lancet Oncol. 2017;18:e246.
60. Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323–8.
61. Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, et al. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc. 2016;138:1430–45.
62. Lim RKV, Yu S, Cheng B, Li S, Kim N-J, Cao Y, et al. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjug Chem. 2015;26:2216–22.
63. Marshall DJ, Harried SS, Murphy JL, Hall CA, Shekhani MS, Pain C, et al. Extracellular antibody drug conjugates exploiting the proximity of two proteins. Mol Ther. 2016;24:1760–70.
64. Rossin R, van Duijnhoven SMJ, ten Hoeve W, Janssen HM, Kleijn LHJ, Hoeben FJM, et al. Triggered drug release from an antibody-drug conjugate using fast “click-to-release” chemistry in mice. Bioconjug Chem. 2016;27:1697–706.